







FIG. 3

*N and C-terminal
TAA Targeted sdAbs*

cx1547, cx309

FR α -targeted Constrained CD3: Protease cleavable
Various protease substrate recognition site: MTSP1, MMP, Granzyme B




FIG. 4A cx1762: Uncleaved




FIG. 4B cx3238: Half cleaved




FIG. 4C cx2190: Fully Cleaved







FIG. 5C




cx2973 cMet x EGFR

Bivalent cMet

Bivalent EGFR

FIG. 5D




cx2979 cMet x EGFR

Monovalent cMet

Bivalent EGFR

FIG. 5E



cx2977 cMet x EGFR

Monovalent cMet

Monovalent EGFR

FIG. 6A







FIG. 6B





66



9
G.
F




FIG. 10A






FIG. 10B




Peak Table

Detector A Channel 1 280nm		
Ret Time	Area	Area%
3.059 min	3065	0.346
7.174 min	9190	1.039
8.001 min	866802	97.966
10.993 min	5799	0.655
	884855	100.000

FIG. 10C








FIG. 12A

Binding to OVCAR5 cells




FIG. 12B

Binding to T cells




FIG. 12C

Binding to OVCAR5 Cells




FIG. 12D

Binding to T cells




FIG. 13A




FIG. 13B




FIG. 14A

Binding to A375 cells




FIG. 14B

Binding to A375 cells




FIG. 14C




FIG. 14D




FIG. 15A




FIG. 15B




FIG. 16A




FIG. 16B




FIG. 16C

cx3490 Binding to Ramos Cells




FIG. 16D

cx3490 Binding to T cells




FIG. 17




FIG. 18




FIG. 19A




FIG. 19B




FIG. 19C




FIG. 19D




FIG. 20A




FIG. 20B





FIG. 20C

Target: CCRF
25nM Ab

●— cx2513; Bi-EGFR $\times$ CD3

cx2973: Bi-cMETxCD3xBi-EGFR

—▲— cx2977; Mono-cMETxCD3xMono-EGFR

cx2979: Mono-cMETxCD3xBI-EGFR


—◆— cx3030; Tet-EGFR $\times$ CD3

☐ No Ab

EGFR/cMET Negative

FIG. 20D

**Target: CCRF
14 Hours**



●— cx2513: Bi-EGFRxCD3

cx2973: Bi-cMETxCD3xBI-EGFR

—▲— cx2977; Mono-cMETxCD3xMono-EGFR

—*— cx2979; Mono-cMETxCD3xBi-EGFR

cx3030: Tet-EGFRxCD3

●—No Ab

EGFR/cMET Negative

FIG. 21A








FIG. 21B





Legend:

- ▽ DART-Fc: B7H3xCD3
- cx3313 - FAB
- ▲ cx3314 - ScFv
- ▼ cx3095




FIG. 22E




FIG. 22D





FIG. 22F

FIG. 23A

Jurkat CD3 NFAT-GFP Reporter +
OVCAR5 (5T4+) Cells @ 24 Hours




□ cx3262: Bi-epitopic 5T4

○ cx3265: Mono-epitopic 5T4

FIG. 23B

Jurkat CD3 NFAT-GFP Reporter +
CCR5 Cells (5T4-) @ 24 Hours



□ cx3262: Bi-epitopic 5T4

○ cx3265: Mono-epitopic 5T4

FIG. 24










FIG. 25













FIG. 28A




FIG. 28B











FIG. 28C
















FIG. 32




FIG. 33




FIG. 34A

B7H3 Positive

CD25 on CD4 T cells, Target Cells: A375




FIG. 34B

B7H3 Negative

CD25 on CD4 T-cells. A549 B7H3 -/-




FIG. 34C

CD25 on CD8 T cells, Target Cells: A375








FIG. 34D

CD25 on CD8 T-cells. A549 B7H3 -/-











FIG. 37






FIG. 38B




FIG. 38C




FIG. 38D

